Safety and Tolerability of AGMB-129 in Healthy Adults: A Dose-Escalation Study for Fibrostenotic Crohn’s Disease

The primary objective of this study is to evaluate the **safety** of AGMB-129 in healthy adults through the administration of multiple doses that are incrementally increased. This is clinically relevant as it aims to establish a safety profile for AGMB-129, which could inform future therapeutic applications, particularly in the context of **Fibrostenotic Crohn’s disease**. No secondary objectives are provided in the available data.

The clinical trial involves participants diagnosed with **fibrostenotic Crohn's disease**. The study population includes both male and female subjects, with an age range categorized under code "3," which typically represents adults. The trial population was selected to include a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Information on lifestyle considerations such as diet, physical activity, or habits is not available. The sponsor has not disclosed key inclusion or exclusion criteria for this study.

The clinical trial is designed to evaluate the safety of **AGMB-129** in healthy adults through a Phase 3 study. The trial will employ a **randomized**, **double-blind**, and **controlled** methodology to ensure the reliability and validity of the results. The study is set to commence on July 9, 2025, with an estimated completion date of October 15, 2025. Participants will be involved in the trial for a duration that aligns with the study's timeline, with specific involvement periods determined by the dosing schedule and follow-up requirements.

The sequence of study visits begins with an inclusion visit, where participants will undergo screening to confirm eligibility based on predefined criteria. This visit will include assessments to ensure participants meet the necessary health standards for trial participation. Following the inclusion visit, participants will attend multiple follow-up visits, during which they will receive incremental doses of AGMB-129. These visits are crucial for monitoring the participants' health and any potential adverse effects, as well as for collecting data on the drug's safety profile. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall impact of the treatment.

Participant involvement is expected to last until the end of the trial, unless specific conditions necessitate early termination. Such conditions may include the occurrence of significant adverse events, non-compliance with study protocols, or withdrawal of consent by the participant. The trial's design and procedures are structured to ensure the safety and well-being of participants while providing valuable data on the safety of AGMB-129 in the context of **fibrostenotic Crohn's disease**.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments, including their names, dosages, or administration routes. The trial documentation does not specify any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 3 study, indicating a focus on confirming the effectiveness of the intervention in a larger patient population. The estimated recruitment start date is July 9, 2025, with an anticipated end date of October 15, 2025. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, Phase 3 trials typically involve comprehensive assessments to determine the intervention's impact on the disease. These assessments may include symptom improvement scores, biomarker levels, or disease remission rates, measured at various timepoints throughout the study. The trial will employ validated methods and instruments to ensure accurate and reliable data collection and analysis. The results will contribute to understanding the intervention's efficacy in the target population.